Vitreous concentration of brimonidine tartrate 0.1% topical applied for neuroprotection

Vitreous concentration of brimonidine tartrate 0.1% topical applied for neuroprotection - Vitreous concentration of topical applied brimonidine tartrate 0.1%

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009982

Enrollment

Registered

2013-02-10

Start date

2013-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergo vitrectomy for macular hole or idiopathic epiretinal membrane

Interventions

topical application of 0.1% brimonidine tartrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient whose age is 20 years old or more when agreement is acquired. Patient who obtained agreement after enough explanation when participating in this study is received. Patients diagnosed with macular hole or idiopathic epiretinal membrane.

Exclusion criteria

Exclusion criteria: History of ocular surgery and inflammation. Patient who is judged inappropriate for study.

Design outcomes

Primary

Measure	Time frame
The concentration of brimonidine in human vitreous and aqueous humore.	—

Countries

Japan

Contacts

Public ContactYoshihiro Takamura

University of Fukui, Faculty of medicine Ophthalmology

ytakamura@hotmail.com0776-61-8403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026